With the rapid development of innovative drugs, investors are increasingly concerned about whether pharmaceutical companies have the ability to "go global"

"Our country's biomedicine, especially innovative drugs, can go to the world, which is of great significance for our country to truly become a big and powerful country in the medical and health industry
.
" Some industry insiders said
.
It is understood that with the rapid development of innovative drugs in China in recent years, overseas markets have become an important target for the development of innovative drugs in China
.
Some analysts believe that whether a company has the ability to "go global" has attracted more attention from investors, and it has become a very big trend in the past two years for pharmaceutical companies to "go global"
.
The author has learned that China's pharmaceutical companies are also making continuous efforts on the road to "going out"
.
For example, Hengrui Medicine has recently made new progress in its international development
.
It is understood that, recently, Hengrui Medicine's SHR-A1904 for injection has obtained the US FDA clinical trial qualification, and SHR-A1904 for injection has been approved to carry out a clinical trial for the treatment of advanced solid tumors in the United States
.
The approved trial is an open, single-arm, multi-center Phase I/IIa clinical study conducted in the United States to evaluate the safety, tolerability, and pharmacokinetics of SHR-A1904 in patients with advanced solid tumors Learning and initial efficacy
.
After obtaining the US FDA clinical trial qualification this time, the clinical research of SHR-A1904 for injection in the treatment of advanced solid tumors is planned to be carried out in the United States, Australia and the Asia-Pacific region
.
Driven by the innovation and international development strategy, Hengrui Medicine has repeatedly allowed the original research of Chinese medicine to shine on the international stage, and its high-quality development has continuously won attention and recognition
.
In recent years, China's innovative drug market has achieved rapid development.
While innovative drugs are developing rapidly, overseas markets have become an important goal for the development of pharmaceutical companies
.
Analysts said that there are more and more products and clinical trials of innovative drugs in China and the United States, which is a general trend
.
At the same time, other analysts also pointed out that the development of internationalization, without the ability to commercialize in the international market, is a better choice for emerging innovative pharmaceutical companies to license patents to large global pharmaceutical companies
.
It is reported that innovative pharmaceutical companies such as BeiGene, Rongchang Biotechnology, and Jiaxian have all promoted innovative products to go overseas through overseas authorization.

.
Taking BeiGene as an example, on January 12, 2021, BeiGene announced the development, production and commercialization of its self-developed anti-PD-1 antibody drug tislelizumab in multiple countries with the global pharmaceutical giant Novartis Hua reached a cooperation and authorization agreement
.
It is reported that this is another important event that BeiGene created a new local anti-cancer drug "going abroad" after Zebutinib was approved by the FDA in the United States in 2019
.
On August 8, 2021, Rongchang Biotechnology reached a global exclusive license agreement with the international biopharmaceutical company Seagen Inc.
(Nasdaq: SGEN) to develop and commercialize its new ADC drug, vedixitrol.
Resist
.
It is understood that with the significant improvement of China's overall economic strength in the past two decades, more and more pharmaceutical companies have begun to explore internationalization
.
According to the industry, internationalization is almost a must for the domestic pharmaceutical industry from the perspective of the country’s overall development trend and industry development stage, whether it is to realize the abbreviated internationalization of a single product through license out, or to integrate R&D, registration, and sales industry chains.
All these are beneficial explorations for the industry
.
"It is not enough for innovative drugs or innovative technologies to be limited to the Chinese market
.
In order for innovative drug companies to be recognized by the market, they must have a certain ability, that is, to get a certain share in the global market
.
" An industry insider said.

.